Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

MLA

Lauren C. Harshman, et al. “Tumor Downstaging as an Intermediate Endpoint to Assess the Activity of Neoadjuvant Systemic Therapy in Patients with Muscle‐invasive Bladder Cancer.” Cancer, vol. 125, May 2019, pp. 3155–63. EBSCOhost, https://doi.org/10.1002/cncr.32169.

APA

Lauren C. Harshman, Nikhil Waingankar, Simon J. Crabb, Matthew D. Galsky, Andrea Necchi, Sumanta K. Pal, Thomas Powles, Rachel Jia, Ulka N. Vaishampayan, Elizabeth R. Plimack, N. Peter Wiklund, Bart S. Ferket, Alberto Martini, Jonathan E. Rosenberg, John P. Sfakianos, Madhu Mazumdar, Evan Y. Yu, & Reza Mehrazin. (2019). Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer. Cancer, 125, 3155–3163. https://doi.org/10.1002/cncr.32169

Chicago

Lauren C. Harshman, Nikhil Waingankar, Simon J. Crabb, Matthew D. Galsky, Andrea Necchi, Sumanta K. Pal, Thomas Powles, et al. 2019. “Tumor Downstaging as an Intermediate Endpoint to Assess the Activity of Neoadjuvant Systemic Therapy in Patients with Muscle‐invasive Bladder Cancer.” Cancer 125 (May): 3155–63. doi:10.1002/cncr.32169.